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Patients with diabetes mellitus experience a more adverse
outcome after acute myocardial infarction compared with
nondiabetic patients, although the mechanisms responsible
for these findings are not clear . From the Multicenter
Investigation of the Limitation of Infarct Size (MILLS)
study, the course of acute infarction in 85 diabetic patients
was compared with that in 415 nondiabetic patients, all of
whom had serial assessments of left ventricular function .
The diabetic patients experienced a more complicated in-
hospital and postdischarge course than did the nondiabetic
patients, including a higher incidence of postinfaretion
angina, infarct extension, heart failure and death, despite
the development of a smaller infarct size and similar levels
of left ventricular ejection fraction .
Although diabetic patients had a worse profile of car-
diovascular risk factors at the time of the index infarction,
the increased incidence of adverse outcomes among them
It has been well established that patients with diabetes
mellitus have a greater morbidity and mortality from cardio-
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persisted despite adjustment for these baseline imbalances .
Diabetic women had a poor baseline risk profile compared
with the other groups categorized by gender and diabetic
status, and experienced an almost twofold increase in
cardiac mortality despite development of the smallest inf-
arct size during the index event . The duration of diabetes
and the use of insulin at the time of the index infarction
were associated with a better in-hospital mortality rate, but
the duration of diabetes did not exert a major influence on
the outcome of the diabetic patients .
The factors responsible for the increased incidence of
adverse outcomes among diabetic patients may be related to
an acceleration of the atherosclerotic process, diastolic left
ventricular dysfunction associated with diabetic cardiomy-
opathy or other unidentified unfavorable processes .
(J Am Coll Cardiol 1 8 ;14 4 -57)
4 
vascular disease than do nondiabetic patients (1-17) . Diabe-
tes is a strong independent risk factor for the development of
atherosclerosis (3,4,8,10,14), predisposes to the develop-
ment of other known risk factors for atherosclerosis such as
hyperlipidemia and hypertension and is associated with
obesity (1,14,18-20) . Diabetic patients also frequently de-
velop primary cardiomyopathy (21) associated with both
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systolic and diastolic left ventricular dysfunction, which may
be due to microangiopathy (22-27), increased extracellular
collagen deposition (22,25,28) or abnormality of calcium
transport in the sarcoplasmic reticulum (2 -32), individually
or in combination .
After an acute myocardial infarction, diabetic patients
experience a higher incidence of congestive heart failure and
death than that of nondiabetic patients (5-7, ,12,13,15,16) . It
is not clear whether these unfavorable outcomes are due to
more severe or more rapidly accelerating epicardial coro-
nary obstructions, the systolic or diastolic dysfunction asso-
ciated with diabetic cardiomyopathy or other factors yet to
be identified. The data base from the Multicenter Investiga-
tion of the Limitation of Infarct Size (MILLS) study provides
a useful tool to explore the mechanisms responsible for
adverse outcomes among diabetic patients because the hos-
pital and follow-up course are well characterized and tests of
left ventricular function were performed during the short-
term hospitalization period and 3 months later .
The purpose of this study, therefore, was to characterize
the hospital and follow-up course of diabetic and nondiabetic
patients and to determine the role of left ventricular dysfunc-
tion in the adverse outcomes observed . Diabetic patients
were also categorized by gender as well as by form of
hypoglycemic therapy used in an effort to investigate the
mechanisms responsible for the differing prognoses in dif-
ferent subsets of patients with diabetes .
Methods
Patient selection . Patients in this data base study are a
subset of those enrolled in the Multicenter Investigation of
the Limitation of Infarct Size (MILLS) study, which was
designed (33) to determine the effect of administration of
propranolol or hyaluronidase to patients within 18 h of the
onset of acute myocardial infarction
. Patients were eligible
for enrollment in the MILLS study if they satisfied the
following inclusion and exclusion criteria and if they and
their physician provided informed consent . The inclusion
criteria were age <76 years, ?30 min of pain typical of
myocardial ischemia and demonstration of electrocardio-
graphic (ECG) evidence of acute myocardial ischemia or
evolving infarction (new Q waves >30 ms in width and ?0 .2
mV in depth or ST segment elevation or depression ?0 . I mV
in at least two related leads), left bundle branch block or
idioventricular rhythm
. Patients were excluded from the
MILLS study if they were in cardiogenic shock (Killip class
IV), had an advanced or terminal illness, had an artificial
cardiac pacemaker or had had an infarction or major surgery
within the previous 2 weeks
. Other exclusion criteria, guide-
lines for standard care and procedures for the administration
of hyaluronidase or propranolol have been described else-
where (33) . Results of the primary study end points have also
previously been reported (34,35) .
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Patients were identified retrospectively for this study if
their index myocardial infarction had been confirmed by the
Creatine Kinase Core Laboratory, there was historical in-
formation concerning the presence or absence of diabetes
mellitus at the time of the index infarction and there was
complete information on the following variables   age, gen-
der, history of cigarette smoking, hypertension, previous
infarction, MB fraction of creatine kinase (MB CK) infarct
size index, type of infarction (Q wave or non-Q wave),
location of infarction (anterior or other) and left ventricular
ejection fraction determined by radionuclide ventriculogra-
phy before and 10 days after randomization
. The presence of
hyperlipidemia was not evaluated as a specific risk factor
because documentation of previous hypercholesterolemia
could not be accurately ascertained in all patients and
because cholesterol levels obtained during the index hospi-
talization could be artifactually altered by the acute event
(36) and would not be representative of the patient's baseline
lipid status .
Data collection .
After enrollment but before randomiza-
tion, baseline measurements were obtained, including a 12
lead ECG and a radionuclide ventriculogram
. Blood samples
for measurement of total and MB CK were collected hourly
during the initial 4 h, at 2 h intervals for the next 4 h and at
4 h intervals for the subsequent 72 h throughout the remain-
ing hospital stay, as previously reported
(33) . Radionuclide
ventriculography was repeated on day 10
. Left ventricular
ejection fraction from multigated equilibrium blood pool
scintigraphy was calculated by a standard technique using a
background-corrected count method from the left anterior
oblique view
(37) . A 12 lead ECG was obtained at  0 min and
at 72 h after initiation of therapy and again on day 10 .
Historical and physical examination data, a summary of
daily clinical events, vital signs and the results of special
procedures and routine laboratory tests were recorded
throughout the course of hospitalization
.
Myocardial infarction was confirmed
if one or more of the
following criteria were met   1) MB CK values ?13 IU/liter in
two or more sequential plasma samples obtained within a 12
h period
; 2) an MB CK value >_ 13 IU/liter in one plasma
sample, if representing a threefold increase above the previ-
ous values
; or 3) a single MB CK value >_ 13 IU/liter if only
one sample was analyzed . Infarct size was estimated from
changes in plasma MB CK (38) . Total plasma CK activity
was assessed by the Rosalki method (3 ) and MB CK by the
glass bead batch adsorption technique (40) .
Congestive heart failure was defined as the presence of
orthopnea, paroxysmal nocturnal dyspnea, pedal edema, an
episode of pulmonary edema or dyspnea on climbing one
flight of stairs or walking_ 100 feet on level ground .
Follow-up .
Follow-up visits to assess interval history and
physical examination were scheduled at 3 and 6 months for
all enrolled patients
. At 3 months a radionuclide ventriculo-
gram was performed at rest and during exercise and at 6
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months a treadmill exercise test was performed . Subse-
quently, the vital status of all patients was ascertained at 6
month intervals by a questionnaire administered by tele-
phone .
End point analyses . The baseline characteristics, hospital
course and clinical outcome of patients were compared for
those patients with a diagnosis of diabetes mellitus identified
before the index infarction and for those who did not have
that diagnosis . Subgroup analyses were performed by cate-
gorizing the two patient groups by gender . To allow for a
thorough evaluation of the effect of gender and diabetic
status on outcome, the risk factor profile, hospital course
and follow-up course of the 500 patients were analyzed in
two manners   first, the data based on gender within diabetic
status group, and then repeated as diabetic status within
gender group . Statistical comparisons were made for each
pair in each group. Patients with diabetes were also subcat-
egorized on the basis of insulin use before the index infarc-
tion and duration of diabetes mellitus . Outcome in the
different patient groups was also analyzed on the basis of
assigned MILLS study treatment   propranolol, hyaluroni-
dase or placebo .
Statistical methods . Student's t test was used to analyze
differences in the means of continuous-type variables, and
chi-square analysis was used for categorical data . Cox
proportional hazards regression model was used to assess
the relative effects of diabetes and other baseline character-
istics on 48 month cardiac mortality (41) . Unadjusted plots of
the estimated cumulative cardiac mortality were produced
by the Kaplan-Meier method (42). Adjusted cardiac mortal-
ity curves were based on the Kalbfleisch and Prentice
discrete hazard model (43) . All probability (p) values were
two-tailed, and a p value of <0 .05 was considered signifi-
cant .
Results
Patient characteristics . The study group consisted of 500
patients with acute myocardial infarction, of whom 85 pa-
tients had a diagnosis of diabetes mellitus before their index
infarction and 415 patients did not . Twenty-five (2 %) of the
diabetic patients were taking insulin, 5 (6%) were taking an
oral hypoglycemic agent and 55 (65%) were on dietary
therapy only . The mean (± standard error) duration of
diabetes was 10 .  ± 1 .2 years . During the acute hospitaliza-
tion the mean minimal fasting serum glucose was 14  .8 ±-
10.8 mg/dl among diabetic patients and 113 .  ± 3 .5 mg/dl
among nondiabetic patients .
Effect of propranolol or hyaluronidase . There was no
difference in outcome based on initial MILLS drug assign-
ment. All patients were, therefore, considered together for
all other analyses irrespective of initial drug assignment .
Risk factor profile (Table 1) . Diabetic patients were older,
more frequently female and had a more frequent history of
hypertension, but fewer were cigarette smokers compared
with nondiabetics . Diabetic and nondiabetic patients had a
similar incidence of previous infarction .
Course of index infarction (Table 2). Compared with
nondiabetic patients, patients with diabetes experienced a
smaller infarct, as measured by both infarct size index and
peak MB CK, and were more likely to develop an infarction
that was anterior in location and non-Q wave in type .
Although left ventricular ejection fraction was similar in both
groups on admission, by 10 days, ejection fraction among
diabetic patients was significantly lower than that of nondi-
abetic patients, albeit still relatively well preserved . Diabetic
patients also experienced more in-hospital complications
than the nondiabetic patients, manifested by a significantly
higher incidence of infarct extension, congestive heart fail-
ure, postinfarction angina, intraventricular conduction delay
and death .
Follow-up course (Table 3) . The mean follow-up period
was 34.  months (range 5 days to 6  .3 months) . Although
diabetic and nondiabetic patients had similar left ventricular
systolic function at 3 months (reflected in the ejection
fraction), diabetic patients had a significantly higher inci-
dence of heart failure, suggesting that their manifestations of
heart failure may have been due to a diastolic rather than a
systolic abnormality . Among the patients with heart failure
during the index hospitalization, there was a trend toward a
higher 48 month cardiac mortality rate for diabetic (30.6%)
compared with that in nondiabetic patients (16 .8%, p =
0 .08). Diabetic patients who survived the index hospitaliza-
tion had a higher 4 year cardiac mortality rate compared with
that of nondiabetic patients (20 .3 versus 12.8%, p = 0 .08) ;
the cumulative 4 year cardiac mortality rate was also higher
in the diabetic group (25 .  versus 14 .5% . p = 0.01) (Fig . IA) .
Among hospital survivors, patients with diabetes tended to
die of fatal reinfarction more frequently than did those
without diabetes (56 .5 versus 34.3%, p = 0 .05 ), but there
were no other differences in the cause of death between the
diabetic and nondiabetic groups (Table 4) .
Analysis after adjustment for differences in baseline char-
acteristics . Analysis of end point variables of heart failure
and mortality was repeated, incorporating an adjustment for
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Table 1 . Risk Factors Before Index Myocardial Infarction (MI)
in 500 Patients
Patient Group
Diabetic
(n = 85)
Nondiabetic
(n = 415) p Value
Mean age (yr) 57 .  ± 1 .2 55 .4 ± 0 .5 0.05
Gender (% female)
38 .8 20 .5 <0 .001
History of
Cigarette use )%) 68 .2 81 .7 0 .005
Hypertension (%)
65 .  50 .1 0.008
Previous Ml (`7o) 25 .  20 .7 NS
52 STONE ET AL .
EFFECT OF DIABETES ON MYOCARDIAL INFARCTION
Table 2. In-Hospital Course and Complications of Index Myocardial Infarction
Data are reported as mean values ± standard error. APDs = atrial premature depolarizations ; AV =
atrioventricular ; CHF = congestive heart failure   LVEF = left ventricular ejection fraction ; MB CK = creatine
kinase-MB fraction ; MI = myocardial infarction   VF = ventricular fibrillation   VPDs = ventricular premature
depolarizations .
the observed differences in baseline variables (Table 1) as
well as important prognostic features from the index hospi-
talization   infarct size index (MB CK), left ventricular ejec-
tion fraction before enrollment and location and type of
infarction (Q wave versus non-Q wave). Despite these
adjustments, patients with diabetes experienced a worse
outcome than did patients without diabetes  more congestive
heart failure during the index hospitalization (p < 0 .001) and
at 6 months (p < 0.001) and a trend toward a higher cardiac
mortality rate (p = 0 .07, Fig . 1B) .
Table 3. Follow-Up Course After Hospital Discharge*
*Mean duration of follow-up 34
.  months (range 5 days to 6  .3 months) .
Abbreviations as in Table 2 .
JACC Vol . 14, No . 1
July 1 8  4 -57
Subgroup Analyses
Subgroup analyses were performed to investigate the
potential contribution of clinical characteristics associated
with the presence of diabetes mellitus to the increased
morbidity and mortality rate observed among diabetics .
1) Effect of gender . Among both diabetic and nondiabetic
patients, women were older than their male counterparts
(diabetic women 61.2 years versus diabetic men 55 .  years,
p = 0 .02 ; nondiabetic women 5  .7 years versus nondiabetic
men 54 .3 years, p < 0 .001) and had a higher incidence of
hypertension (diabetic women 81 .8% versus diabetic men
55.8%, p = 0 .01) and a lower incidence of cigarette smoking
(diabetic women 51 .5% versus diabetic men 78 .8%, p =
0.008), although there was no significant difference in the
incidence of previous infarction . Compared with nondiabetic
women, diabetic women had a lower incidence of cigarette
smoking (diabetic women 51 .5% versus nondiabetic women
77 .7%, p = 0.005) and a higher incidence of hypertension
(diabetic women 81 .8% versus nondiabetic women 55.3%,
p = 0.008) . There were no differences in risk factors between
diabetic and nondiabetic men .
Hospital course . Despite the small numbers of patients in
the subgroups, there was a consistent trend toward a higher
in-hospital mortality rate among diabetic patients of either
gender compared with that in their nondiabetic counterparts
(diabetic women   .1% versus nondiabetic women 2 .4%, p =
0.103; diabetic men 5 .8% versus nondiabetic men 1 .8%, p =
0.08) . Among the diabetic patients, there was no gender
Diabetics
(n = 85)
Nondiabetics
(n = 415) p Value
Infarct size index (MB CK) (g •e glm 2 ) 13 .6 ± 1 .36 17 .8 ± 0 .77 0 .003
Peak MB CK (IU/liter) 116 .7 ± 10 .4 15 .7 ± 5 .1 <0 .001
Anterior location of MI (%)
76 .5
62
.7 0 .02
Development of non-Q wave MI (%) 44.7 33 .5 <0 .05
LVEF
Before randomization (%) 45 .2± 1 .8 47.0±0.7 NS
10 days after randomization (%) 44 .2 ± 1 .7 48 .7 ± 0.7 <0 .02
Development of CHF (%) 42.4 24 .3 <0 .001
Postinfarction angina (%) 42 .4 31 .1 <0 .05
Infarct extension (%) 14.1 7 .5 <0 .05
Development of VPDs (%) 2 .4 43 .4 <0 .02
Nonfatal VF (%) 3 .5 8 .7 NS
Development of APDs (%)
2 .4 26
.3 NS
Development of AV conduction block (%) 21 .2 1  .1 NS
Development of intraventricular 23 .5 13 .0 0 .01
conduction delay (%)
Death (%)
7 .1 1 . 
0 .00 
Diabetics
(n = 7 )
Nondiabetics
(n = 407) p Value
LVEF
at 3 months (%) 47 .1 ± 1 .7 46.8 ± 0.8 NS
Incidence of CHF (%)
At 3 months 27 .6 16.1 <0 .02
At 6 months 30 .1 10 .7 <0 .0001
Incidence of angina (%)
At 3 months 37 .7 43 .2 NS
At 6 months 36 .1 38 .4
NS
Incidence of reinfarction (%)
At 3 months 1 .3 3 .3
NS
At 6 months 2 .7 0 .8 NS
Cumulative 4 year cardiac 25 .  14 .5 0 .01
mortality rate (%)
JACC Vol . 14, No . I
July 1 8   4 -57
0,35
0.30-
A. Unadjusted
P=0 .01
0.25
Diabetes
h
0.20-
r r ---
W 0.15-
O
Q
0 .10
0.05
v
0
~O
0.35-
	
p=0.067
B
. Adjusted
1
0 .30-
0.25
Q
Diabetes
0.20-
0.15 -
'1
~	
0.10-
0 .05
- No Diabetes
6 12
18 24 30 36 42 48
MONTHS AFTER ENTRY
Figure 1 . Cumulative cardiac mortality curves after myocardial
infarction by history of diabetes . A, Unadjusted ; B, Adjusted for the
following risk factors known to affect prognosis   age, gender,
history of cigarette smoking, history of systemic hypertension,
previous infarction, infarct size index (MB CK), left ventricular
ejection fraction on admission, anterior location of index infarction
and type of infarction (Q wave or non-Q wave) .
difference in infarct size, location or type of infarct that
developed or complications of infarction . Diabetic women
experienced a smaller infarction than nondiabetic women,
although they had a higher incidence of infarct extension (21 .2
versus 7 .1%, p = 0.03) and, consequently, a reduced left
ventricular ejection fraction at 10 days compared with nondi-
abetic women (45 .  ± 2. % versus 53 .7 ± 1 . %, p = 0 .03) .
Diabetic men also had a smaller infarct than did nondiabetic
men. Although diabetic men did not have a higher incidence
of infarct extension compared with nondiabetic men, they had
a higher incidence of anterior infarction (78 .  versus 62 .4%,
p = 0 .02) associated with a lower ejection fraction at 10 days
(43 .0 ± 2 .1% versus 47 .4 ± 0 .8%, p = 0 .06) and experienced
congestive heart failure in the hospital almost twice as fre-
quently (46.2 versus 24 .6%, p = 0 .001) .
Follow-up course . Although there was no difference based
on gender or diabetes status in the number of patients who
died from coronary heart disease, arrhythmias, heart failure
or sudden death after hospital discharge, a significant majority
of diabetic women died from acute reinfarction (66.7%) com-
pared with diabetic men (45.5%), nondiabetic women (11 .1%)
and nondiabetic men (42 .3%) (p = 0.02) . The increased
incidence of heart failure among diabetic patients appeared to
involve diabetic men and women equally . At 6 months,
however, diabetic women appeared to have a greater inci-
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Table 4. Causes of Death in Diabetics and Nondiabetics After
Hospital Discharge
MI = myocardial infarction
.
dence of heart failure than that of diabetic men (44 .0 versus
22. %, p = 0 .06) . Among hospital survivors, diabetic women
had a higher cardiac mortality rate than did diabetic men (33 .3
versus 12.2%, p = 0 .02) and a higher total 4 year mortality
rate (3  .4 versus 17 .3%, p = 0 .02) . Within each gender,
diabetic patients developed heart failure significantly more
frequently than did their nondiabetic counterparts at 6 months
(diabetic women 44.0% versus nondiabetic women 1  .7%,
p = 0 .02 ; diabetic men 22 . % versus nondiabetic men 8 .4%,
p = 0 .002) . Diabetic women had more than a twofold higher
cumulative 4 year cardiac mortality rate compared with that
of nondiabetic women (3  .4 versus 15 .3%, p = 0 .005) .
2) Effect of insulin use at the time of the index infarction .
There were no significant differences in the risk factor profile
of diabetic patients categorized on the basis of insulin use .
Patients who used insulin had a higher in-hospital mortality
rate than did patients who did not use insulin (16 .0 versus
3 .3%, p = 0.04) and developed a non-Q wave infarction more
frequently (63 .3 versus 36 .0%, p = 0 .02), but there were no
other significant differences and complications in the in-
hospital course. Left ventricular ejection fraction was simi-
lar at the 3 month follow-up visit, although the incidence of
heart failure at the 6 month visit among insulin users was
more than twice that of noninsulin users (52 .4 versus 21 .2%,
p = 0.008). Angina was also significantly more common
among insulin users than among noninsulin users at the 6
month follow-up visit (61 .  versus 25 .2%, p = 0 .004) . There
was no significant difference in the incidence of nonfatal
recurrent infarction, cardiac death over the follow-up course
or the mechanism of death .
3) Effect of duration of diabetes mellitus . There were no
significant differences related to the duration of diabetes in
the hospital course and follow-up period .
Discussion
Prognosis of diabetics versus nondiabetics after myocardial
infarction . Our results demonstrate that patients with diabe-
tes mellitus have a worse profile of known cardiovascular
risk factors at the time of their index myocardial infarction
than do patients without diabetes mellitus, and experience a
Diabetics Nondiabetics p Value
Total no
. of deaths 23
70
Specific cause of death
Coronary heart disease (%) 82 .6 85 .7 NS
Arrhythmia (%) 30 .4 35 .7 NS
Fatal MI (%) 56 .5 34 .3 0.05 
Congestive heart failure 1%) 34 .8 34.3 NS
Sudden death (%) 17 .4 28 .6 NS
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more complicated hospital course, including a higher in-
hospital mortality rate . Their follow-up course is also more
complicated than that of nondiabetic patients, and is char-
acterized by a higher incidence of congestive heart failure,
despite similar left ventricular systolic function, and a higher
cardiac mortality rate among hospital survivors due, at least
in part, to a higher incidence of fatal reinfarction . The
increased incidence of adverse outcomes in diabetic patients
persists despite adjustment for their excess of adverse base-
line features .
The results further indicate that diabetic women experi-
ence a particularly poor outcome after acute myocardial
infarction . Diabetic women have a poor baseline risk profile
compared with the other groups categorized by gender and
diabetic status, and have almost twice the cardiac mortality
rate of the other groups despite development of the smallest
infarct size during the index event . Diabetic patients who
used insulin experienced a higher incidence of in-hospital
death than did nondiabetic patients who did not use insulin,
but the duration of diabetes at the time of the index infarc-
tion did not exert a major influence on the outcome of the
diabetic group . It is not clear whether the poor outcome
among the diabetic patients observed both during the in-
hospital phase and among hospital survivors was due to
more extensive epicardial coronary artery disease existing at
the time of the index infarction, the adverse effects of a
diabetic cardiomyopathy, the presence of more rapidly ac-
celerating atherosclerosis or an excess of baseline risk
factors not included in the statistical model used to adjust for
known risk factors .
Effect of diabetes on the course of myocardial infarction . It
has long been appreciated that diabetic patients experience a
poor outcome after acute infarction (44,45) . Since the advent
of coronary care units, retrospective (5-7, ,12,16,45-48) and
prospective (13,15) studies have compared the course of
infarction between diabetic and nondiabetic patients and
indicated a poor outcome for diabetic patients, who had a
hospital mortality rate ranging from 16% to 51% compared
with a rate of  % to 26% among nondiabetic patients . In
addition to an increased mortality rate, diabetic patients also
experience more morbid events compared with nondiabetic
patients, including congestive heart failure (6 .7,12,15,48),
ventricular arrhythmias (5,7), atrioventricular and intraven-
tricular conduction disturbances ( ,15) and reinfarction and
unstable angina (4 ) . Within the group with diabetes, pa-
tients with certain characteristics were found to have a
worse prognosis than that of patients without the character-
istics, which included female gender (5-7,15,45), use of oral
hypoglycemia drugs (5,15), use of insulin ( ), presence of
obesity (6,45) and anterior location of infarction (47) . Some
studies (13) have reported that diabetic patients have a
higher incidence of other risk factors that may be associated
with their adverse outcome, whereas others have reported a
similar incidence of pre-existing risk factors (16) such as
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hypertension ( ,12), prior infarction ( ,12), type and location
of infarction (12,4 ) and even a similar (48), if not smaller
(12), infarct size compared with nondiabetics .
Differences in the observed characteristics of the diabetic
patients in the various studies may be due to small sample
size or inclusion of only diabetic patients requiring insulin
(13) . The "hypercoagulable state" associated with diabetes,
characterized by increased platelet aggregability, reduced
fibrinogen survival, and a defective fibrinolytic mechanism
(50) may also contribute to the poor outcome observed in
diabetic patients . Our study confirms that diabetic patients
experience a poor in-hospital outcome compared with that of
nondiabetic patients, and adds new insight suggesting that
the increased incidence of heart failure during the index
hospitalization may be due in part to a left ventricular
diastolic abnormality .
Follow-up course in diabetic and nondiabetic patients .
Despite the general similarity of risk factors at the time of the
index infarction, diabetic patients consistently experience a
follow-up mortality rate 1 .5- to 3-fold that of nondiabetic
patients (6,7,12,13,16,48) . The observed 4 year cardiac mor-
tality rate in the MILLS study of 25 . % in diabetic patients
compared with 14 .5% for nondiabetic patients is similar to
the previously reported mortality rates in similar postinfarc-
tion patient groups (13,16) . The increased incidence of
congestive heart failure after acute infarction is also similar
to that in previously reported studies (see below) . Consistent
with our results, diabetic men have been noted to have an
increased incidence of reinfarction (51), but this has not been
observed among diabetic women .
Our results suggest new insight into possible mechanisms
responsible for the unfavorable outcome in diabetic pa-
tients . Although the diabetic patients in the MILLS study had
an excess of adverse risk features compared with nondia-
betic patients (Table 1), the poor outcome of the diabetic
patients, characterized by an increased incidence of conges-
tive heart failure during the index hospitalization and at 3
and 6 months later and a trend toward a higher incidence of
cardiac death, persisted after adjustment for these differ-
ences in baseline characteristics . Unique to the MILLS data
base is the assessment of left ventricular systolic function by
radionuclide ventriculography in addition to clinical assess-
ment, both during the index hospitalization and at the 3
month follow-up visit . The studies of ventricular function
indicate the presence of relatively well preserved systolic
function at a time when diabetic patients have significantly
more manifestations of congestive heart failure . The discrep-
ancy between frequent signs and symptoms of heart failure
in the setting of relatively preserved systolic function sug-
gests that the "failure" may be due in large part to diastolic
dysfunction and decreased left ventricular compliance . Fur-
thermore, the fact that there was a trend toward a higher 48
month cardiac mortality rate in diabetic patients who expe-
rienced heart failure during the index hospitalization com-
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pared with that in nondiabetic patients who experienced
heart failure suggests that the mechanism and significance of
heart failure may be different in patients with and without
diabetes .
Diabetes mellitus as a risk factor for epicardial coronary
atherosclerosis . Although the presence of diabetes mellitus
is a known independent risk factor for the development of
events related to ischemic heart disease (4,8,10,14,1 ,20), it
also predisposes to or is associated with an increased inci-
dence of other known risk factors such as hypertension,
obesity and hyperlipidemia (1,14,18,1 ). The effect of diabe-
tes mellitus on the development of epicardial coronary
atherosclerosis, however, remains somewhat controversial .
Necropsy studies indicate that patients with juvenile (52) or
adult (53,54) onset diabetes have more severe and extensive
coronary obstructions than do "control subjects" matched
for age, gender and other risk factors . Waller et al . (55)
observed that the average number of coronary arteries
obstructed was similar in diabetic and nondiabetic patients,
but that the patients with diabetes had more severe stenoses .
They found no differences in the pattern or extent of
obstructions based on the age of onset of diabetes, duration
of diabetes, type of hypoglycemic therapy or degree of
control of hyperglycemia . In addition, they found that the
acceleration of epicardial atherosclerotic obstructions was
observed only in patients whose onset of diabetes was before
age 46 years (56) . Although Hamby and Sherman (57) found
no difference in the extent of coronary artery disease based
on the form of therapy used, they did observe a significant
correlation between duration of diabetes and number of
coronary arteries obstructed .
Because coronary angiography was not routinely per-
formed in the MILLS study, the distribution and rate of
progression of coronary atherosclerotic lesions in diabetic
and nondiabetic patients could not be ascertained . Diabetic
patients tended to experience more frequent fatal reinfarc-
tion than did nondiabetic patients in our study (58 .6 versus
40 .5%, p = 0 .0 ), especially diabetic women (73 .3%), com-
pared with diabetic men (42 . %), nondiabetic women
(15 .0%) and nondiabetic men (4  .2%) (all p = 0 .006), sug-
gesting that epicardial stenoses were indeed either more
severe, more extensive or progressed more rapidly in the
diabetic group. The "hypercoagulable state" associated
with diabetes (50) may further contribute to the vulnerability
for reinfarction in this group of patients . However, the
observation that congestive heart failure was significantly
more common in diabetic than in nondiabetic patients during
the index hospitalization and during the follow-up period,
despite a similar and reasonably well preserved ejection
fraction, suggests that an abnormality of diastolic ventricular
function also contributed to the adverse outcome in the
diabetic patients .
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Effect of diabetes on diastolic left ventricular function .
There have been extensive studies in experimental animals
(23,28,2 ,58) and patients (5 -65) indicating that diabetes
mellitus is associated with a cardiomyopathic process that
affects left ventricular diastolic function . The diastolic ab-
normality may occur early in the course of diabetes, is
unassociated with any symptoms or other manifestations of
heart disease and is generally present in diabetic patients
requiring insulin, especially those with juvenile onset diabe-
tes (60,61,63,65,66) . It is unclear whether the diastolic ab-
normality, characterized by decreased left ventricular com-
pliance and slow myocardial relaxation, is due to the
presence of microaneurysms in the myocardium (22), arte-
riolar infiltration with periodic acid-Schiff-positive gly-
coprotein material (23-25), thickening of the capillary basal
lamina (26,27), increased extracellular collagen deposition
(22,25,28) or abnormalities of calcium reuptake into the
sarcoplasmic reticulum (2 -32) . Other studies (7, ,12,
15,16,48,4 ) have similarly observed that diabetic patients
experience significantly more manifestations of heart failure
during and after hospitalization than do nondiabetic patients,
but have not followed serial systolic left ventricular function
to determine the mechanism or mechanisms responsible for
the heart failure .
The effect of gender on outcome . The increased late
cardiac mortality rate among diabetic patients who survived
the index hospitalization was predominantly a result of the
extremely high mortality rate in diabetic women (33 .3%)
compared with that in nondiabetic women (13 .3%, p =
0.015), diabetic men (12 .2%, p = 0.02) and nondiabetic men
(12.7%, p = 0 .002) . Diabetic women have been consistently
observed to experience a worse prognosis than that of
diabetic men, both in studies of the acute course of in-
farction (5-7,15,45) and in long-term epidemiologic studies
(4,8,10,14). It is not clear why diabetic women experience
such a poor prognosis . In our study, the increased mortality
of diabetic women was due to an increased incidence of fatal
reinfarction after hospital discharge, perhaps related to the
unfavorable risk factor profile that was noted at the time of
the index infarction . Data from the Framingham study (67)
and from a previous report from the MILLS study (68),
however, indicate that the adverse prognosis observed in
women is due not solely to a poorer risk factor profile, but
also to an independent, as yet unknown factor . It is unknown
whether there are gender differences in the "hypercoagu-
lable state" associated with diabetes (50) that may contrib-
ute to the gender differences in mortality . It is also not clear
whether there is a relation between the increased mortality
rate observed in the diabetic women and the diastolic
abnormalities that may be responsible for the increased
incidence of heart failure .
The effect of insulin use on outcome . Some investigators
have noted that either insulin (6 -71) or oral hypoglycemic
agents (71) can reverse the hemodynamic disturbances as-
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sociated with diabetic cardiomyopathy in animals with ex-
perimental diabetes . Neither we nor others (3, ,16,62) ob-
served a protective effect of insulin use on either the
incidence of heart failure or death . The number of patients
treated with insulin in our and other studies, however, is
very small .
Effect of beta-adrenergic blocker therapy on outcome .
Recent studies (72,73) have demonstrated that the beneficial
effect of long-term beta-adrenergic blocker therapy for sec-
ondary prevention is particularly pronounced among dia-
betic patients . We did not observe a protective effect of a
beta-blocker in the diabetic patients, most likely because the
therapy in the MILLS study was prescribed only for the 10
days after the index infarction .
Limitations of the study . Although clinical and laboratory
data were recorded prospectively in all patients and end
point analyses were performed by individuals blinded to
patient characteristics or medication use, this study is a
posthoc investigation of the data base and its results should,
therefore, be viewed in this context . However, the study is
based on prior hypotheses from previous studies . Because of
the number of statistical comparisons that were made, some
statistically significant relations may have been due to
chance and may not constitute true biologic significance . We
have emphasized those concepts that were proposed by our
prior hypotheses and that were supported by a large number
of statistically significant and internally consistent relations .
Clinical implications . Diabetics experience a worse prog-
nosis than nondiabetics during the course of acute infarction
and in the follow-up period . This adverse outcome is related
in part to an increased incidence of other coronary risk
factors among diabetics, but also appears to be a result of an
independent factor related to the presence of diabetes mel-
litus . This independent diabetic factor may be related to an
acceleration of the atherosclerotic process or the presence of
diabetic cardiomyopathy, or both . The diastolic abnormality
associated with the diabetic cardiomyopathy may be respon-
sible for many of the manifestations of heart failure in these
patients and may predispose to other untoward events
.
Attention to both the coronary disease and the diastolic left
ventricular dysfunction may aid in the management of dia-
betic patients after infarction .
We are grateful to Kathleen Carney for assistance in the preparation of this
manuscript .
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